Similarly, BRCA1/2 mutation carriers with ovarian cancer show higher response rates and longer overall survival after platinum-based chemotherapy than nonhereditary patients (Ben David et al, 2002; Tan et al, 2008). The gene discussed is BRCA1; the disease is ovarian carcinoma.